相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Virology
Ancuta Lupu et al.
Summary: Pediatric systemic lupus erythematosus is a chronic autoimmune disorder with a highly variable course and prognosis. The use of immunosuppressive therapies and underlying comorbidities increase the risk of severe COVID-19 and poor outcomes in pediatric SLE patients. This review analyzes newly diagnosed cases of pediatric SLE following COVID-19 and examines the impact of COVID-19 on patients with existing pediatric SLE.
Article
Medicine, General & Internal
Seth Flaxman et al.
Summary: COVID-19 was responsible for more than 940,000 deaths in the US, including at least 1,289 children and young people aged 0 to 19 years, with at least 821 deaths occurring between August 1, 2021, and July 31, 2022. The objective of the study was to determine whether COVID-19 is a leading cause of death in children and young people in the US. The findings showed that COVID-19 ranked among the top 10 causes of death in this age group, highlighting its significant impact. Rating: 9/10.
Article
Immunology
Tatsuki Ikuse et al.
Summary: The emergence of the BA.5 variant significantly impacted children in Japan, with an increase in hospitalizations for complex febrile seizure. The estimated vaccine effectiveness against hospitalization during BA.5 predominance was 75%. It is important to increase COVID-19 vaccination rates in children to prevent hospitalizations and prepare for future variant outbreaks.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2023)
Review
Biology
Amber N. Edinoff et al.
Summary: COVID-19 has emerged as a global pandemic, resulting in a significant burden on healthcare systems and healthcare workers. Severe cases of COVID-19 can lead to acute respiratory distress syndrome (ARDS) and high mortality rates. The use of IL-6 inhibitor tocilizumab has shown promising results in targeting the cytokine storm syndrome associated with COVID-19.
Article
Respiratory System
Alpana Waghmare et al.
CLINICS IN CHEST MEDICINE
(2023)
Article
Pediatrics
Jessica Laird-Gion et al.
Summary: With the emergence of new variants of SARS-CoV-2, particularly the Omicron sub-variants, the severity of illness from COVID-19 has decreased despite higher transmissibility. However, there is limited data on how the history, diagnosis, and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) have changed with the evolution of SARS-CoV-2 variants. A retrospective cohort study was conducted on hospitalized MIS-C patients between April 2020 and July 2022, categorizing patients into Alpha, Delta, and Omicron variant cohorts based on admission dates and variant prevalence data. The study found that more MIS-C patients had a documented history of COVID-19 in the two months before MIS-C during the Omicron era compared to the Alpha era, but there were no significant differences in clinical severity across different variant eras.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Article
Infectious Diseases
Kensuke Shoji et al.
Summary: This study aimed to investigate the clinical features and outcomes of pediatric patients with COVID-19 infected by the Delta variant. The results showed that although there was a higher admission rate to the intensive care unit in the Delta VOC era, the overall outcomes in children with COVID-19 remained favorable.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Medicine, General & Internal
Jennifer Hammond et al.
Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
R. L. Gottlieb et al.
Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Immunology
Byung-Han Ryu et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2022)
News Item
Medicine, General & Internal
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Rheumatology
Lianne Kearsley-Fleet et al.
Summary: This is the most significant investigation to date of COVID-19 in children and young people with rheumatic and musculoskeletal diseases (RMDs), and it has found that patients with severe systemic RMDs and obesity are more likely to be hospitalized.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Infectious Diseases
Frank Zhu et al.
Summary: This review provides a concise and updated summary of pediatric COVID-19 diagnosis and management. The proportion of pediatric cases has significantly increased with the emergence of the Omicron variant. Although children present with milder symptoms, severe disease can still occur. There is a relative lack of pediatric data in COVID-19 management, and most recommendations are based on adult data. Children may have typical and atypical clinical presentations, and there is a risk of post-infectious complications. Diagnosis relies on nucleic acid amplification tests, and management primarily involves supportive care, with vaccination strongly recommended.
CURRENT INFECTIOUS DISEASE REPORTS
(2022)
Article
Medicine, General & Internal
Fatih Haslak et al.
Summary: This study aims to describe the clinical features and outcomes of children and late adolescents with inflammatory rheumatic diseases (IRD) and COVID-19, and comparing their severity risks with healthy children.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Yuta Aizawa et al.
Summary: This review provides updates on COVID-19 in children in Japan, including the waves of outbreaks, changes in clinical features, and vaccination rates. Despite the impact on children, the clinical outcomes in Japan have been favorable compared to some other countries, and there is a need to improve the vaccination rate.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2022)
Review
Virology
Haifa Khemiri et al.
Summary: This study found that the incidence of SARS-CoV-2 infection was underestimated in infants, with most infected children presenting with asymptomatic or mild symptoms. The prevalence of COVID-19 varied by country, with the highest reported in the United States (22.5%). With the emergence of the B.1.617.2 Delta and B.1.1.529 Omicron variants, these variants appear to affect a large proportion of the younger population with similar clinical manifestations to adults and significant hospitalization rates.
Article
Virology
Keita Wagatsuma et al.
Summary: The study assessed the effects of ambient temperature and mobility patterns on COVID-19 transmission in Japan, finding a higher risk of transmission associated with colder temperatures and higher retail and recreation mobility. These findings provide valuable insights for public health policies.
Article
Medicine, General & Internal
Vijairam Selvaraj et al.
Summary: This study found that baricitinib was associated with a significant reduction in 28-day mortality for hospitalized patients with COVID-19, although its effect on progression to IMV or ECMO was not significant. When used in conjunction with standard care, baricitinib improved mortality in COVID-19 patients.
Review
Pediatrics
Sophia Tsabouri et al.
PEDIATRIC CLINICS OF NORTH AMERICA
(2021)
Article
Rheumatology
Claudia Sengler et al.
Summary: This study investigated the clinical manifestations, course, and outcome of SARS-CoV-2 infection among children and adolescents with rheumatic and musculoskeletal diseases. The majority of patients had a mild course of infection with good outcomes, and the infection did not significantly impact the disease activity of the underlying condition in most cases.
Review
Immunology
Mejbah Uddin Bhuiyan et al.
Summary: This study reviewed the epidemiological and clinical characteristics of COVID-19 infection in children under five years old, revealing that approximately half of the cases were infants, about half of the cases were asymptomatic, and a small portion required hospitalization. Ongoing surveillance is needed to better understand the transmission and clinical presentation of COVID-19 in young children.
Article
Public, Environmental & Occupational Health
Eva Leidman et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Pediatrics
Daniel Clemente et al.
Summary: This study assessed baseline characteristics and outcomes of pediatric patients with rheumatic and musculoskeletal diseases (RMD) and COVID-19, finding no differences in outcomes based on disease type. The study suggested that previous comorbidities and glucocorticoid use increased the risk of hospital admission.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Pediatrics
D. Sofia Villacis-Nunez et al.
Summary: There are few reports of COVID-19 in pediatric patients with rheumatic diseases. Hospitalized patients were more likely to be African American and have cardiovascular disease, while the use of medium/high-dose corticosteroids and immunosuppressive drugs increased the risk of hospitalization. Symptoms such as fever, dyspnea, chest pain, and rash were high-risk indicators for hospitalization in this population.
PEDIATRIC RHEUMATOLOGY
(2021)
News Item
Medicine, General & Internal
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Rheumatology
Dawn M. Wahezi et al.
Summary: The task force has approved 39 guidance statements, which were combined to form a total of 33 final guidance statements based on similar recommendations. All final statements received median vote ratings within the highest tertile of agreement and were associated with either moderate consensus (n = 5) or high consensus (n = 28).
ARTHRITIS & RHEUMATOLOGY
(2021)
Editorial Material
Medicine, General & Internal
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Infectious Diseases
Jonathan Mannheim et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
(2020)
